Abstract: Amorphous compounds of Formula I, solid dispersions of amorphous compounds of Formula I, pharmaceutical compositions comprising the same and their use in the treatment and prevention of diseases and disorders associated with cannabinoid CB1 receptor are described. The solid dispersions comprise a compound of Formula I dispersed in a solid matrix comprising a pharmaceutically acceptable polymer having a glass transition temperature of at lest 50° C.

Abstract: The present application relates to novel narcotic formulations having a decreased injection abuse potential In a representative embodiment, the formulation comprises methadone hydrochloride (6-dimethylamino-4,4-diphenylheptan-3-one, a synthetic opiod), meglumine, cellulose, lactose, and magnesium stearate The application further illustrates methods for making the contemplated formulations.